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Abstract
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al., nearly half a 
century ago, the subsequent development of a vaccine, understanding of the patho‐
genesis, and the advent of antiviral drugs, the prevalence of chronic hepatitis B has 
decreased from approximately 5% to 3.61% of the worldwide population. Despite this 
improvement, approximately 248 million individuals are still infected with the virus. 
Effective treatment of chronic hepatitis B is extremely important as a positive correla‐
tion has been observed between baseline viral load and the risk for the development 
of hepatocellular carcinoma (HCC). While there have been significant advancements 
in the management of hepatitis B virus with available nucleos(t)ide analogues, there 
remains much work to be done to prevent HCC. The molecular mechanism and the 
subsequent carcinogenesis and progression of chronic HBV carriers to HCC remain in 
large part poorly understood. While current treatment with nucleos(t)ide analogues has 
succeeded in maintaining undetectable viral levels in patients with chronic hepatitis B, 
eradication of the virus has not been possible, and there remains the risk of develop‐
ment of HCC. Therefore, more effective treatment regimens aiming for HBV cure are 
urgently needed. With multiple new therapies in the pipeline, the future of treating 
hepatitis B is an exciting and developing one, and hopefully, it will soon become a 
disease of the past.
Keywords: hepatitis B, hepatocellular carcinoma, anti‐HBV drugs, nucleos(t)ide 
analogues, HBV cure, HBV therapy
1. Introduction
In the past 50 years, since the discovery of the hepatitis B virus [1], the development of a 
vaccine, understanding of the pathogenesis, and the advent of antiviral drugs, the preva‐
lence of chronic hepatitis B has decreased from approximately 5% to 3.61% of the worldwide 
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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 population [2]. Nevertheless, hepatitis B remains a common and frequently encountered con‐
dition, affecting approximately 248 million individuals in the world.
The vast majority of individuals with chronic hepatitis B are located in Africa and Eastern 
Asia. In the United States, over 2 million Americans are afflicted and the majority (1.5 mil‐
lion) are immigrants from foreign countries [3, 4]. Effective treatment of chronic hepatitis 
B remains of extremely high importance, as patients who have been found to have higher 
baseline viral loads have been shown to have increased rates of hepatocellular carcinoma 
(HCC) [5]. As the treatment landscape of hepatitis B has shifted from earlier regimens of 
interferon and lamivudine to newer agents, namely tenofovir and entecavir, there remains 
much work to be done to reduce viral loads in patients and prevent long‐term sequelae of 
cirrhosis and HCC. This chapter will discuss the natural history and potential carcinogenesis 
of hepatitis B virus, and will discuss current and possible future treatments, and the hope 
for an eventual cure.
2. Natural history of hepatitis B virus
In contrast to many known pathogens, hepatitis B virus (HBV) is not directly cytopathic 
to hepatocytes. Although not completely understood, the injury to the liver cells is in part 
through a host immune mechanism. Replicating HBV in hepatocytes produces HBsAg par‐
ticles and virions which are taken up by the antigen presenting cells. The viral proteins are 
degraded to peptides, which are presented on the cell surface bound to MHC class I or II 
molecules. MHC class I molecules are recognized by CD8 T cells and MHC II by CD4 T cells. 
Virus‐specific CD8+ cytotoxic T cells, with help from CD4+ T cells, recognize viral antigens 
presented on MHC class I chains on infected hepatocytes. This recognition reaction can lead 
to either direct lysis of the infected hepatocyte or the release of interferon‐γ and TNF‐a, 
which can down‐regulate viral replication in surrounding hepatocytes without direct cell 
killing [6].
In order to further discuss advancements in the understanding and treatment of HBV, it is 
important first to review the natural history of the disease. The cycle of chronic HBV infection 
primarily consists of five phases as shown in Figure 1 [7, 8].
In the initial infection phase, or so‐called immune tolerant phase, patients have very minimal 
inflammation. The hallmark of this phase is that these patients are found to be positive for 
HBeAg with high viral loads, typically >20,000 IU/mL (> 105 copies/mL) [9]. Conversely, they 
have normal aminotransferase (ALT) levels, and near‐normal liver parenchyma on biopsy 
[10]. This “immune tolerant” phase is relatively short when HBV is acquired in adulthood, 
but can be sustained for much longer periods of time with infections acquired at birth or in 
early childhood [11, 12]. The risk of progressing to the chronic carrier state is significantly 
higher in infections acquired at a younger age, including up to a 90% risk when infected 
perinatally, as compared to a less than 1% risk of progression when acquired as an adult 
[13, 14].
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Following the “immune tolerant” phase, patients progress into the “immune clearance” phase, 
which again consists of high viral loads and a persistently positive HBeAg. However, at this 
point patients begin experiencing increased inflammation, with elevated ALT levels, and 
potential hepatic decompensation [15, 16]. It is at this point when the viral DNA levels of 
HBV begin to decline, as does the presence of HBeAg. This is in large part due to the activated 
T‐cell immune response, and subsequent destruction of infected hepatocytes [6]. An outcome 
of the immune clearance phase is HBeAg seroconversion, which has been found to be critical 
in predicting progression to cirrhosis and HCC.
Following HBeAg seroconversion, patients typically enter an “inactive carrier” phase, where 
HBeAg becomes undetectable, and HBe antibodies (anti‐HBe) appear [17]. Typically the 
patient's viral load is low or undetectable and ALT returns to normal. Biopsy at this time will 
show minimal fibrosis and mild hepatitis. If the patient had experienced severe liver injury 
during the “immune clearance” phase, cirrhosis can also be present [17].
During the “reactivation phase”, patients who were previously infected with HBV again have 
a detectable viral load, elevated ALT, and inflammation seen on biopsy [18]. In contrast to the 
“immune tolerant” phase, however, these patients do not have HBeAg positivity, but do have 
positive anti‐HBe. As a result, this phase is known as the “HBeAg negative chronic hepatitis B” 
phase. As with the “immune clearance” phase, these patients can exhibit marked inflammation 
and hepatocyte destruction, and can experience hepatic decompensation during this phase.
The final phase of HBV infection is known as the “remission” or “inactive” phase, in which 
HBsAg may become negative, but anti‐HBe and anti‐HBc remain positive. Transaminases are 
normal at this time, and HBV viral loads are very low or undetectable.
Figure 1. Five phases of chronic hepatitis B *. * Adapted from Tong et al. (7) and modified by Halegoua‐DeMarzio and Hann (8).
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It is important to remember that once patients are infected, they remain positive for anti‐HBc 
IgG throughout even after they lose HBsAg and after they acquire anti‐HBs. Also, anti‐HBe 
may often remain detectable.
Furthermore, as part of the infection of HBV into human hepatocytes, HBV DNA converts 
itself into a covalently closed circular DNA, known as cccDNA, inside the hepatocyte nucleus 
[19]. This cccDNA serves as a template for transcription of HBV viral mRNAs, which translate 
and produce HBV proteins as well as provide a template for HBV DNA synthesis [20]. Thus, 
although a patient's viral load may be undetectable and HBsAg may become negative, the 
patient is not cured of HBV, as cccDNA will remain within hepatocytes.
3. Current treatments for chronic hepatitis B
Anti‐HBV treatment drugs have made significant progress in improving the health and lifes‐
pan of patients with HBV. Beginning with interferon in 1991, therapies have become more 
targeted with lower resistance profiles and more tolerable side effects. The ultimate goal of 
hepatitis B treatment is to achieve remission, i.e., sustained suppression of viral replication. 
This, in turn, will lead to prevention of progression to cirrhosis and/or HCC. Several studies 
have demonstrated the reduction of HCC development with antiviral drugs [21–26].
Currently there are six approved treatments for HBV. The details of drugs and efficacy are 
shown in Table 1.
Pegylated interferon alpha‐2a. The first treatment approved for HBV in 1991, pegylated 
interferon alpha‐2a, or peg‐IFN α‐2a, is an immunomodulator, which also displays a weak 
effect against the virus itself [27]. It is administered as an injection, which patients receive 
weekly for a total treatment of 48 weeks. It has been shown to produce HBeAg seroconver‐
sion in 27% of patients, and 25% of patients develop an undetectable HBV DNA load [28]. It 
has been shown to have the best response for those individuals with genotype A with either 
ALT > 2x ULN or low HBV DNA, and for genotypes B and C with ALT > 2x ULN and low 
HBV DNA [29]. Although an effective treatment in the past, peg‐IFN α‐2a is a small percent‐
age of current HBV treatments in the US [30]. Much of this is likely due to the requirement of 
an injection weekly, a large percentage of patients who fail to respond, and a significant side 
effect profile.
Lamivudine. The first nucleoside analogue approved for treatment of HBV, lamivudine 
(LMV) is a reverse transcriptase inhibitor. Functioning as a nucleoside analogue, it inhibits 
DNA synthesis of HBV. The treatment is extended across 1 year, and has been associated with 
a seroconversion rate of 16–18% at 1 year, and increases up to nearly 50% at 4 years [31, 32]. It 
is the least expensive of the nucleotide/nucleoside analogues, and is safe to use in pregnancy, 
which is one of its most common uses in current times. LMV has also been shown to reduce 
the rate of development of both fibrosis and HCC [33]. The most significant evidence of the 
effectiveness of LMV was shown in a randomized, controlled trial by Liaw et al., comparing 
LMV versus placebo in patients with chronic hepatitis B and high serum levels of HBV DNA 
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[33]. The primary endpoint was progression of liver disease identified as either an increase in 
Child‐Pugh score, bleeding from esophageal varices, or development of HCC. The study was 
discontinued early given that it demonstrated such a clear benefit of LMV compared to pla‐
cebo [33]. Despite the success that has been shown with LMV, its use is limited, mainly due to 
the high incidence of resistance, especially compared with newer nucleotide/nucleoside ana‐
logues [34]. In one study, however, much lower resistance was observed if the baseline HBV 
DNA was < 106 copies/mL [35], and there has been an extensive review as to the discrepancies 
* Adapted from Halegoua‐De Marzio and Hann (8).
Table 1. Treatment options of chronic hepatitis B*.
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of LMV resistance among the multiple studies regarding the incidence of LMV resistance [36]. 
LMV also reduced vertical HBV transmission from highly viremic mothers to their newborns 
[37]. Currently, the use of oral antiviral agents during the first and second trimesters of preg‐
nancy is not recommended.
Adefovir dipivoxil. The first nucleotide analogue, adefovir dipivoxil (ADV), was approved 
by the FDA for use in 2002. Similar to LMV in its mechanism of action, ADV functions as a 
reverse transcriptase inhibitor. As compared with LMV, however, ADV had both an increased 
antiviral potency, and an intrinsic stereoscopic structure that prevents emergence of viral 
resistance. HBe seroconversion was achieved in 12% of patients after 1 year of therapy with 
ADV, and a 53% rate of histological improvements in patients who were positive for HBeAg 
[38]. Of the patients who did seroconvert, it was found to be sustained in 91% of these patients 
[39]. Like LMV, however, prolonged use is associated with an increase in resistance, pro‐
gressing from 3% at 2 years to 29% at 5 years [40]. Due to this, in addition to associated renal 
toxicity, the use of ADV has become increasingly rare with the development of newer, more 
effective therapies.
Entecavir. The second nucleoside analogue approved for treatment of chronic HBV, entecavir 
(ETV), was approved by the FDA for treatment in 2005. It has been shown to be superior at 
reducing HBV DNA levels, as compared with LMV [41]. In a phase 3 study comparing ETV 
to LMV after 1 year of treatment, patients were found to have improved virological response 
with HBV DNA < 400 copies/mL (67% vs 36%), improvement on histologic examination (72% 
vs 62%), and improvement in aminotransferases, namely ALT (78% returned to normal as 
compared to 70%) [41]. In longer term studies, up to 96% of patients had improvement in 
histologic examination, and improvement in fibrosis score after 6 years [42]. Improvements 
were even found in patients with cirrhosis. Entecavir also was shown to keep HBeAg‐positive 
patients with HBV DNA levels below 300 copies/mL in 94% of patients at 5 years [43]. It has 
been shown to cause viral suppression quicker than ADV, and has been shown to significantly 
decrease the incidence of HCC in chronic HBV patients, with a 3.7% incidence in the ETV 
group as compared with 13.7% in the untreated group [23]. One of the most important fea‐
tures of entecavir, and a reason why it remains one of the two recommended treatments for 
chronic HBV today, is that it has a high genetic barrier and a very low incidence of resistance. 
The cumulative incidence of resistance after 6 years has been found to be 1.2% in nucleoside‐
naïve patients [44].
Telbivudine. Another nucleoside analogue similar in structure to LMV, telbivudine (TLV) was 
approved by the FDA for treatment of chronic HBV in 2006. In HBeAg‐positive patients, the 
seroconversion with TLV was found to be 22% at 1 year and 30% at 2 years [45, 46]. Viral sup‐
pression to less than 300 copies of DNA/mL was found to be 60% after 1 year of TLV therapy, 
and 56% after two years of therapy [45, 46]. Unfortunately, although TLV was shown to have 
promising effects and to have a higher barrier to resistance than LMV, resistance has been 
found to be as high as 21.6% in HBeAg‐positive patients, and 8.6% in HBeAg‐negative patients 
[47]. Because of this, TLV currently is not a recommended first‐line treatment. However, TLV 
is shown to be highly effective for those with low baseline HBV DNA and achieves undetect‐
able HBV DNA at week 24. Therefore, TLV is highly effective for patients with the above 
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characteristics [48]. Furthermore, recent studies report the renoprotective effect of TLV, its 
role in preventing ADV‐induced nephrotoxicity, and increased GFR improvement of renal 
function in liver transplant patients and in patients with compensated or decompensated 
HBV‐related liver diseases [49–52]. The rate of vertical transmission was reduced when tel‐
bivudine was given to mothers with high viral loads during the third trimester of pregnancy 
[53]. Currently, the use of oral antiviral agents during the first and second trimesters of preg‐
nancy is not recommended.
Tenofovir. The most recent nucleotide analogue, tenofovir disoproxil fumarate (TDF), was 
approved by the FDA for treatment of patients with chronic hepatitis B in 2008. Structurally 
similar but a more potent drug than ADV, TDF has been shown to produce more viral 
suppression in HBeAg‐positive patients, with 76% of patients achieving viral loads < 400 
copies/mL as compared with 13% of patients treated with ADV after 48 weeks of treatment 
[54]. ALT normalization, histologic improvement, and HBsAg loss were all also found to 
be significantly increased in patients treated with TDF as compared with ADV [54]. Data 
have shown an excellent continued response, with a 7‐year viral suppression (HBV DNA 
levels < both 69 IU/mL and 29 IU/mL) of greater than 99% in both HBeAg‐negative and 
HBeAg‐positive patients [55]. In addition to its effectiveness, TDF has also been shown to 
have an extremely favorable resistance profile [56]. Due to the effectiveness and the virtual 
absence of resistance, TDF has been recommended as a first‐line treatment in patients with 
chronic hepatitis B.
Several currently used guidelines are shown in Table 2.
Since the majority of chronic hepatitis B patients in the United States are immigrants form 
endemic countries, especially from Asia, where infection takes place commonly at birth or in 
early childhood, Asian‐American algorithm is frequently used for treatment for this majority 
of HBV patients. These guidelines are as follows [7]:
1. For HBeAg (+) or (‐) patient with chronic HBV with DNA > 104 copies/mL (> 2000 IU/mL) 
and ALT > ULN, treatment should be started with a first‐line agent (ETV or TDF).
2. For cirrhotic patients with detectable HBV DNA, treatment should be started with ETV or 
TDF.
3. In HBeAg (‐) patients with HBV DNA > 104 copies/mL (> 2000 IU/mL) and normal ALT, a 
liver biopsy is recommended. If not available, further stratification for risk factors (albu‐
min ≤ 3.5 g/dL or platelets ≤ 130,000/μL, HCC first degree relative, age ≥ 40, male gender, 
ALT > 30 U/L for male and 19 U/L for female) should be conducted prior to treatment.
4. Monitoring treatment: Test for serum ALT every 3 months. Measure HBV DNA every 3 
months until negative, then every 3–6 months. Measure HBeAg every 6 months until 
negative, then test for anti‐HBe.
5. After seroconversion from HBeAg‐positive to anti‐HBe, test for HBsAg every 12 months. 
In HBeAg (‐) patients, test for HBsAg every 12 months after sustained suppression of 
HBV DNA.
Treatment of Chronic Hepatitis B: An Update and Prospect for Cure
http://dx.doi.org/10.5772/66724
137
6. Monitoring of resistance: Viral breakthrough with confirmation of single drug resistance 
requires switching to another first‐line oral antiviral agent.
7. Surveillance for HCC with Alpha‐fetoprotein (AFP) and abdominal ultrasound should be 
performed every 6 months in HBsAg‐positive patients with chronic hepatitis, cirrhosis, 
and for patients with a family history of HCC.
8. With regard to stopping treatment, for HBeAg (+) patients, following HBeAg seroconver‐
sion, continue consolidation for 1–2 years before stopping therapy. However, the relapse 
rate is high, and longer consolidation therapy may be needed. For HBeAg (‐) patients, 
antiviral therapy should be indefinite therapy until HBsAg seroconversion.
Before the antiviral drugs became available, 25–40% of HBV‐infected individuals used to 
progress from chronic hepatitis to cirrhosis and eventually to HCC as shown in Table 3
*EASL (European Association for the Study for the Liver) (72),
US Algorithm (73)
APASL (Asian Pacific Association of the Study of the Liver (74)
AASLD (American Association of the Study of Liver Diseases) (75)
Asian American Algorithm (7)
ULN = Upper limit of normal; NS = Not stated).
* UNL: 30 IU/mL for men, 19 IU/mL for women
2000 IU/mL = 104copies/mL
20,000 IU/mL=105copies/mL
Table 2. Current treatments for hepatitis B in chronic hepatitis, as recommended by different guidelines (ref. 7, 69–72).
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In their 13‐year follow‐up study of HBV‐infected carriers, Chen et al. have noted that higher 
baseline viral loads were associated with an increased rate of HCC [5] (Figure 2).
During the last 10 years, several studies have demonstrated that antiviral treatment signifi‐
cantly reduced the incidence of HCC [21–26]. However, all these treatment modalities are 
to suppress HBV replication. They do not fully eradicate the virus. The inability to eradi‐
cate HBV still leaves infected individuals at the risk for HCC. Current anti‐HBV treatment 
can achieve “functional cure” but not “complete cure”, the terminology as coined by Zeisel 
et al. [19]. (Table 4).
Table 3. Natural history of chronic hepatitis B infection.
Figure 2. Higher baseline viral loads are associated with increased rate of HCC. *From Chen, et al. (5).
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4. Hepatocarcinogenesis
The pathogenesis for HBV‐related HCC is not fully understood, but is likely multifactorial. 
HBV DNA level is a known factor, and the presence of HBV DNA has been shown to have 
a linear relationship to the development of HCC [5]. A high viral load leads to a persistent 
immune response against hepatocytes, with persistent inflammation, regeneration, and fibro‐
sis. This up‐regulated state of inflammation can in turn predispose to a malignant transforma‐
tion [57]. Several studies have also suggested that the integration of HBV DNA into the host 
DNA can lead to chromosomal instability and eventual gene rearrangement. These rearrange‐
ments can, in effect, lead to deregulation and instability of gene expression, subsequently 
leading to oncogenesis [58–60].
The association with chronic HBV and HCC has been described as early as the 1970s. The land‐
mark cohort study by Beasley et al. in 1981, which studied over 22,000 men in Taiwan, showed 
a significant association between chronic HBV carriers and the development of HCC. In this 
study, the relative risk of development of HCC in men with chronic HBV was determined to 
be 63 times higher as compared with uninfected individuals [61]. This study also designated 
the HBV vaccine (plasma vaccine by Blumberg and Millman followed by the recombinant 
vaccine) as the first “Cancer Vaccine” by the World Health Organization. The increased risk of 
HCC in patients with HBV has repeatedly been confirmed with smaller, more recent studies. 
Although HBsAg seroconversion and viral suppression are typically associated with protec‐
tion against HCC, patients who have cleared their viral load have still been found to acquire 
HCC. This is likely due to the continued presence of cccDNA, in a mechanism that is not well 
understood. Studies have also shown that HCC development is better associated with patients 
who have had active HBV infection for longer time periods, including patients who were 
infected at younger ages. Thus, it is thought that HCC progression is likely a result of HBV 
replication itself and subsequent liver injuries that follow [62]. It also raises the point that in 
individuals infected earlier, carcinogenic processes may have already been in play prior to the 
halt of viral replication later in life, and the ability of HBV to integrate into the infected host's 
hepatocyte genome is one of the most important direct pro‐oncogenic properties.
In addition to chronic HBV carrier status, other risk factors have been identified which pre‐
dispose patients with hepatitis B to HCC. These factors include co‐infection with hepatitis 
C (HCV), a family history of prior HCC, concurrent alcohol use, and a predominance of 
genotype C [63–66]. Additionally, the presence of core promoter mutations, the most com‐
mon of which is the HBx protein, a potent activator of multiple genes, including oncogenes, 
has been discovered [67].
*Ab, antibodies; cccDNA, covalently closed circular DNA
Adapted and edited from Zeisel et al. (19)
Table 4. Definitions of HBV Cure.
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5. Future treatments
Most current guidelines recommend against HBV treatment of patients in the immune toler‐
ant phase (Table 2). However, recent reports have indicated evidence that immune reactivity 
is in fact present in patients during this immune tolerant stage [68–70]. There is a growing 
opinion that to prevent HCC, we should consider earlier treatment of chronic hepatitis B as 
lucidly reasoned by Zoulim and Mason [71]. Given the emergence of HCC even in patients 
who had become seronegative, these guidelines should be readdressed in order to treat 
patients starting at a younger age, in order to prevent progression of disease and the develop‐
ment of HCC, as viral suppression alone has not proven effective for the absolute prevention 
of HCC. Additionally, the required long‐term therapy imposes not only financial burden but 
may also put patients at risk for potential drug resistance and unknown toxicity.
Along with nucleoside/nucleotide analogues, treatment may need to include targeting the 
cccDNA and inhibiting viral entry into the newly formed hepatocytes. This may be accom‐
plished via a T‐cell vaccine which specifically targets HBV, enhancing innate immunity 
with toll‐like receptor agonist. Several compounds have been identified which have the 
*cccDNA, covalently closed circular DNA; DAA, direct‐acting antiviral; FDA, US Food and Drug Administration; HCC, 
hepatocellular carcinoma; HTA, host‐targeting agent; IFN, interferon; LTβR, lymphotoxin‐β receptor; NTCP, sodium 
taurocholate co‐transporting polypeptideAdapted and edited from Zeisel et al. (19)
Table 5. Emerging drugs against HBV.
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potential for eradicating the virus. The clinical trials are in progress at different phases 
to further investigate these compounds [19]. Among these are direct‐acting antagonists 
against the HBV capsid, against the HBV cccDNA, and against the HBV RNA. While the 
targets enhancing the innate immunity are mainly in the preclinical phase, they pose excit‐
ing possibilities for the future of HBV treatment. The potential drugs in the pipelines are 
shown below [19] (Table 5).
6. Conclusion
While there have been significant advancements in the understanding and management 
of hepatitis B virus, there remains much to be learned. The molecular mechanism and the 
subsequent carcinogenesis and progression of chronic HBV carriers to HCC remain in large 
part poorly understood. While significant improvements in treatment of HBV continue to be 
made, research toward HBV complete cure and the treatment landscape now is much differ‐
ent than it was at the end of the twentieth century. The development of nucleotide and nucleo‐
side analogues, particularly entecavir and tenofovir, has significantly improved the ability of 
chronic HBV carriers to remain with undetectable viral levels. There remains, however, the 
possibility of development of HCC, in part likely in the early stages of infection, as well as the 
viral incorporation into hepatocyte DNA. Therefore, more effective treatment regimens need 
to be developed, and the prospect of treating individuals at earlier stages of HBV should be 
addressed. With multiple new therapies in the pipeline, the future of treating hepatitis B is an 
exciting and developing one, and hopefully, it will soon become a disease of the past.
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